Lv3
318 积分 2023-11-24 加入
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
15天前
已完结
SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
3个月前
已完结
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
3个月前
已完结
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
3个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
3个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
4个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
4个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
4个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
